cognitive functioning News
-
Altoida Partners With GN Group to Research and Develop New Cognitive Assessment Technology to Detect Mild Cognitive Impairment
Altoida, Inc. an AI company pioneering next-generation neurological disease diagnostics, and GN Group, a global leader in intelligent audio solutions, have signed a multi-year strategic partnership to research and develop new digital biomarkers for identifying Mild Cognitive Impairment (MCI). The research will serve as the backbone for new augmented reality tools to help at-risk individuals gain ...
-
Vybion New Drug Webinar for Huntington`s Patients
Vybion (NY) conducted a webinar, sponsored by the Huntington's Disease Society of America (HSDA), for patients and caregivers on a new Gene Therapy drug called INT41. The company CEO described this new drug class called Intrabodies and how INT41 works in Huntington's Disease along with clinical development plans. The company believes that Intrabodies can achieve both the specificity and safety of ...
By Vybion
-
Alkahest Announces Multiple Presentations at the Society for Neuroscience Annual Meeting
Alkahest, Inc., a clinical stage biotechnology company focused on developing transformative therapies to treat age-related diseases, today announced upcoming presentations at the Society for Neuroscience (SFN) 49th Annual Meeting being held October 19 – October 23, 2019 at the McCormick Place Convention Center in Chicago. The Company will present data from recent studies demonstrating the ...
-
NIEHS Funds Six Early-Career Researchers For Innovative Science
New grants totaling $3 million will go to six outstanding early-career scientists, bridging a funding gap to independent biomedical research. The National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health, created the award to encourage early stage researchers who want to discover how our environment influences human health. The highly competitive ...
-
Alkahest Announces Initiation of Phase 2 Study AKST1210-201 Exploring Treatment of Cognitive Impairment in End Stage Renal Disease Patients
Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced the initiation of a clinical study to explore the use of an extracorporeal medical device to remove excess Beta-2 microglobulin (B2M) from circulation for the treatment of cognitive impairment in patients undergoing hemodialysis for ...
-
Alfa Chemistry Integrates Its Supply of Dietary Supplement Ingredients
Alfa Chemistry, a reputable global supplier of research chemicals and materials, has recently announced the integration of its dietary supplement ingredients supply. This move aims to streamline the company's operations and enhance its ability to meet the growing demand for high-quality dietary supplement ingredients. Dietary supplements have gained significant popularity in recent years, with ...
-
Lilly`s donanemab slowed Alzheimer`s disease progression in Phase 2 trial: full data presented at AD/PD™ 2021 and published in NEJM
Phase 2 TRAILBLAZER-ALZ results presented today by Eli Lilly and Company (NYSE: LLY) at the 15th International Conference on Alzheimer's & Parkinson Diseases™ 2021 (AD/PD™ 2021) held virtually March 9-14, 2021 and published simultaneously in the New England Journal of Medicine (NEJM) expand on previously reported top-line data that found donanemab met its primary endpoint and ...
-
Longeveron Announces Initiation of Phase 2a Clinical Trial of Lomecel-B for the Treatment of Alzheimer’s Disease
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today the initiation of its Phase 2a clinical trial evaluating Lomecel-B as a treatment for Alzheimer’s disease (AD). The first patient has consented to participate in the trial and ...
-
Multi-Type Animal Cognitive Behavioral Tests for Disease Research
In the pursuit of advancing disease research and its treatment, animal cognitive behavior is studied in a wide range of animal species. The innovative multi-type animal cognitive behavioral tests are set to complement disease research methodology, enabling scientists to gain deeper insight into the complexities of cognitive functioning and its implications in various pathological conditions. ...
By Protheragen
-
AI -driven analysis of Parkinson’s Disease Dementia clinical trial reveals potential molecular mechanism of blarcamesine (ANAVEX2-73) in restoring key neurodegenerative pathways
Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical study. Initial results were presented by Ariana Pharma at the Alzheimer’s Association International Conference (AAIC 2022) in San Diego, in ...
-
Longeveron Enters into Cooperative Research and Development Agreement with the US Department of Veterans Affairs for its Phase 2 Alzheimer’s Trial
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, announced today a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) for the addition of a Miami VA clinical site to its ongoing Phase 2 ...
-
Altoida upsizes its Series A Round to $20.3M to Advance Its First in Class AI-Powered Neurocognitive Assessment Platform
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that it has successfully raised an additional $14 million for its Series A round with new and existing investors. The investment was co-led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, ...
-
Increase in cancers and fertility problems may be caused by household chemicals and pharmaceuticals
Chemicals which disrupt the hormone system – also known as 'endocrine disrupting chemicals' (EDCs) – may be a contributing factor behind the significant increases in cancers, diabetes and obesity, falling fertility, and an increased number of neurological development problems in both humans and animals, according to a review of recent scientific literature commissioned by the European ...
-
TIKOMED’S ILB® restores brain energy metabolism following severe traumatic brain injury in the rat demonstrated in data published by the journal Antioxidants
A new study on TIKOMED’s lead drug candidate, ILB®, addressing one of the underlying causes of neurodegeneration in acute and chronic diseases was published in Antioxidants today. The data from the rodent model studying severe traumatic brain injury (sTBI), showed that a single post-injury injection of ILB® has beneficial effects on the metabolic damages caused by sTBI. “This ...
By TIKOMED AB
-
This year`s Medical Innovation Summit will highlight neurosciences innovation
Thousands of researchers, investors, entrepreneurs and those who are simply curious will descend upon the Cleveland Convocation Center October 26-28 for Cleveland Clinic Innovations Medical Innovation Summit. This year’s theme, The Neurosciences: Memory. Mood. Movement, will cover all aspects of the human brain and how it functions and malfunctions. “This is our marquee event,” ...
-
Longeveron Announces Publication of Lomecel-B Phase 2b Trial Design in Journal of Frailty and Aging
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today publication of the design and rationale from its recently completed Phase 2b aging frailty clinical trial with Lomecel-B in the Journal of Frailty and Aging. This peer-reviewed ...
-
Computerized Cognition Test Provides Better Assessment than Observation
Research published in the Journal of Alzheimer’s Disease this week suggests healthy older adults are less capable of observing their own cognitive decline over an 18 month period than Cogstate’s computerized brief battery (CBB). The study, conducted by neuropsychologists, also indicated that close family members were unable to perceive decline in the cognitive behavior of their ...
By IOS Press
-
Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration
Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Ariana Pharma (Cambridge, MA and Paris, France) today announced an artificial intelligence-driven, precision medicine collaboration. This collaboration is expected to identify biomarkers of response to refine patient selection to guide and accelerate the clinical development of Cyclerion’s investigational therapeutics for neurological and ...
-
The Ultimate List of Attractive MedTech M&A Targets
Updated May 12, 2021 to reflect 10 new additions, based on recent analyst reports. We’ve also updated the existing companies on the list to reflect recent business developments. From time to time, medtech analysts will call out companies in the private sector that they believe investors should be keeping tabs on. Here is our ultimate list, compiled from analyst reports, of private ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you